


IMAGE

Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system

A Lu^{1,6}, MA Steiner¹, N Whittle², AM Vogl¹, SM Walser¹, M Ableitner¹, D Refojo¹, M Ekker³, JL Rubenstein⁴, GK Stalla¹, N Singewald², F Holsboer¹, CT Wotjak¹, W Wurst^{1,5} and JM Deussing¹

¹Max Planck Institute of Psychiatry, Kraepelinstrasse, Munich, Germany; ²Department of Pharmacology and Toxicology, University of Innsbruck, Innsbruck, Austria; ³Department of Biology, Center for Advanced Research in Environmental Genomics, University of Ottawa, Ottawa, ON, Canada; ⁴Nina Ireland Laboratory of Developmental Neurobiology, University of California San Francisco, San Francisco, CA, USA and ⁵Institute for Developmental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany



Molecular Psychiatry (2008) **13**, 989; doi:10.1038/mp.2008.107

Conditional mouse mutants overexpressing corticotropin-releasing hormone (CRH) restricted to the central nervous system exhibit enhanced active stress-coping behavior. A highly flexible gain-of-function mouse model was created by combining the properties of the ubiquitously expressed *ROSA26* locus with those of the *Cre/loxP* system. The knock-in of a *Crh-LacZ* expression unit, which is sensitive to activation by Cre recombinase, allows the spatio-temporally controlled overexpression of CRH at different dosages. In control mice (left), only endogenous CRH expression was detectable in the brain, whereas heterozygous (middle) and homozygous (right) CRH-COE-Nes mice expressed increasing levels of exogenous CRH throughout the brain. The pattern of CRH induction paralleled the activation of the simultaneously introduced *LacZ* reporter gene (left brain half). CRH-COE-Nes mice exhibited a marked gene-dosage-dependent increase in active stress-coping behavior as reflected by reduced immobility in the forced swim test (bottom), which depends on catecholaminergic transmission and enhanced activation of the *locus coeruleus*. For more information on this topic, please refer to article by Deussing *et al.* on pages 1028–1042.

⁶Current address: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Clinical Endocrinology Branch, Bethesda, MD, USA.